Kangstem Biotech Co., Ltd. (KOSDAQ:217730)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,260.00
+145.00 (6.86%)
At close: Jul 27, 2026

Kangstem Biotech Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
3,4233,5727,74612,70416,30112,405
Revenue Growth
-74.22%-53.88%-39.03%-22.06%31.41%35.75%
Gross Profit
605.07845.014,3251,6434,8732,689
Operating Income
-17,493-17,668-14,842-22,777-20,558-22,736
Net Income
-10,140-10,482-7,669-21,949-20,236-21,348
Earnings Per Share
-128.50-150.86-136.00-540.61-533.40-766.61
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
32,62338,56918,26737,36036,67856,585
Total Debt
9,4199,4008,45613,60913,36914,044
Net Cash (Debt)
23,20429,1699,81123,75123,30942,542
Net Cash Growth
2.70%197.32%-58.69%1.90%-45.21%115.13%
Net Cash Per Share
294.06419.79173.97584.98614.401527.64

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-14,827-11,676-18,987-16,498-18,864-16,994
Capital Expenditures
-573.23-660.84-593.45-1,392-712.42-4,631
Free Cash Flow
-15,400-12,337-19,581-17,890-19,576-21,624
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
17.68%23.65%55.84%12.93%29.89%21.68%
Operating Margin
-511.02%-494.56%-191.62%-179.29%-126.12%-183.28%
Pretax Margin
-295.79%-293.00%-91.44%-182.13%-124.02%-175.83%
Profit Margin
-296.22%-293.41%-99.01%-172.77%-124.14%-172.10%
FCF Margin
-449.89%-345.33%-252.79%-140.82%-120.10%-174.32%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
53.5561.0814.6210.556.7410.00